AU2001253119A1 - A gene differentially expressed in breast and bladder cancer and encoded polypeptides - Google Patents

A gene differentially expressed in breast and bladder cancer and encoded polypeptides

Info

Publication number
AU2001253119A1
AU2001253119A1 AU2001253119A AU2001253119A AU2001253119A1 AU 2001253119 A1 AU2001253119 A1 AU 2001253119A1 AU 2001253119 A AU2001253119 A AU 2001253119A AU 2001253119 A AU2001253119 A AU 2001253119A AU 2001253119 A1 AU2001253119 A1 AU 2001253119A1
Authority
AU
Australia
Prior art keywords
breast
bladder cancer
differentially expressed
encoded polypeptides
gene differentially
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
AU2001253119A
Other versions
AU2001253119B2 (en
AU2001253119A2 (en
Inventor
Melinda A. Borrello
Elizabeth E. Evans
Maurice Zauderer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Rochester
Original Assignee
University of Rochester
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Rochester filed Critical University of Rochester
Priority claimed from PCT/US2001/010855 external-priority patent/WO2001074859A2/en
Publication of AU2001253119A1 publication Critical patent/AU2001253119A1/en
Publication of AU2001253119A2 publication Critical patent/AU2001253119A2/en
Application granted granted Critical
Publication of AU2001253119B2 publication Critical patent/AU2001253119B2/en
Priority to AU2006202984A priority Critical patent/AU2006202984B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

AU2001253119A 2000-04-04 2001-04-04 A gene differentially expressed in breast and bladder cancer and encoded polypeptides Ceased AU2001253119B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2006202984A AU2006202984B2 (en) 2000-04-04 2006-07-12 A gene differentially expressed in breast and bladder cancer and encoded polypeptides

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US19446300P 2000-04-04 2000-04-04
US60/194,463 2000-04-04
PCT/US2001/010855 WO2001074859A2 (en) 2000-04-04 2001-04-04 A gene differentially expressed in breast and bladder cancer and encoded polypeptides

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2006202984A Division AU2006202984B2 (en) 2000-04-04 2006-07-12 A gene differentially expressed in breast and bladder cancer and encoded polypeptides

Publications (3)

Publication Number Publication Date
AU2001253119A1 true AU2001253119A1 (en) 2002-01-03
AU2001253119A2 AU2001253119A2 (en) 2003-03-27
AU2001253119B2 AU2001253119B2 (en) 2006-04-13

Family

ID=22717696

Family Applications (2)

Application Number Title Priority Date Filing Date
AU5311901A Pending AU5311901A (en) 2000-04-04 2001-04-04 A gene differentially expressed in breast and bladder cancer and encoded polypeptides
AU2001253119A Ceased AU2001253119B2 (en) 2000-04-04 2001-04-04 A gene differentially expressed in breast and bladder cancer and encoded polypeptides

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AU5311901A Pending AU5311901A (en) 2000-04-04 2001-04-04 A gene differentially expressed in breast and bladder cancer and encoded polypeptides

Country Status (10)

Country Link
US (3) US7268207B2 (en)
EP (1) EP1272636B8 (en)
JP (1) JP2004502408A (en)
CN (2) CN1610743A (en)
AT (1) ATE404669T1 (en)
AU (2) AU5311901A (en)
CA (1) CA2413211A1 (en)
DE (1) DE60135315D1 (en)
NZ (1) NZ522282A (en)
WO (1) WO2001074859A2 (en)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2413211A1 (en) 2000-04-04 2001-10-11 University Of Rochester A gene differentially expressed in breast and bladder cancer and encoded polypeptides
US7135278B1 (en) 2000-09-29 2006-11-14 University Of Rochester Method of screening for therapeutics for infectious diseases
US20020164346A1 (en) * 2001-02-14 2002-11-07 Nicolette Charles A. Altered peptide ligands
WO2003004989A2 (en) * 2001-06-21 2003-01-16 Millennium Pharmaceuticals, Inc. Compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer
US7563882B2 (en) * 2002-06-10 2009-07-21 University Of Rochester Polynucleotides encoding antibodies that bind to the C35 polypeptide
US9809654B2 (en) 2002-09-27 2017-11-07 Vaccinex, Inc. Targeted CD1d molecules
WO2004087058A2 (en) * 2003-03-28 2004-10-14 Vaccinex, Inc. Targeted mhc class i alpha3 vaccine delivery systems
WO2005099361A2 (en) * 2003-07-10 2005-10-27 Vaccinex, Inc. MHC CLASS I - PEPTIDE-ANTIBODY CONJUGATES WITH MODIFIED β2-MICROGLOBULIN
EP1708751B1 (en) * 2003-12-04 2011-09-28 Vaccinex, Inc. Methods of killing tumor cells by targeting internal antigens exposed on apoptotic tumor cells
US20050266425A1 (en) * 2003-12-31 2005-12-01 Vaccinex, Inc. Methods for producing and identifying multispecific antibodies
US20050260659A1 (en) * 2004-04-23 2005-11-24 Exagen Diagnostics, Inc. Compositions and methods for breast cancer prognosis
AU2007261247A1 (en) * 2006-06-22 2007-12-27 Vaccinex, Inc. Anti-C35 antibodies for treating cancer
US9603922B2 (en) * 2007-02-21 2017-03-28 Vaccinex, Inc. Modulation of NKT cell activity with antigen-loaded CD1d molecules
JP2010540534A (en) 2007-09-28 2010-12-24 イントレキソン コーポレーション Therapeutic gene switch constructs and bioreactors for the expression of biotherapeutic molecules and uses thereof
NZ586544A (en) 2007-12-26 2012-07-27 Vaccinex Inc Anti-c35 antibody in combination with an ani-her2 antibody in cancer therapies and methods
PT2385980T (en) 2009-01-08 2018-06-26 Albert Einstein College Medicine Inc Bacterial vaccines with cell wall-associated ceramide-like glycolipids and uses thereof
JP5784583B2 (en) * 2009-04-01 2015-09-24 ザ・ユニバーシティ・オブ・ブリティッシュ・コロンビア Semaphorin 3C (SEMA3C) inhibitory therapeutic agent, method and use
CN102639555B (en) * 2009-09-24 2015-11-25 加利福尼亚大学董事会 Bladder cancer specific ligand peptide
US9371352B2 (en) 2013-02-08 2016-06-21 Vaccinex, Inc. Modified glycolipids and methods of making and using the same
RU2729116C2 (en) * 2015-12-16 2020-08-04 Гритстоун Онколоджи, Инк. Identification, production and use of neoantigens
IL273030B2 (en) * 2017-09-05 2024-03-01 Gritstone Bio Inc Neoantigen identification for t-cell therapy
KR20200087143A (en) 2017-10-10 2020-07-20 그릿스톤 온콜로지, 인코포레이티드 Identification of new antigens using hot spots
JP2021503897A (en) 2017-11-22 2021-02-15 グリットストーン オンコロジー インコーポレイテッド Reduced junction epitope presentation for nascent antigens
KR102318018B1 (en) 2019-07-05 2021-10-28 한국생산기술연구원 Manufacturing mehtod of mandrel for manufacturing micro product, manufacturing method of mold for manufacturing micro product and mold for manufacturing micro product
US20230109070A1 (en) * 2019-10-18 2023-04-06 The Board of Trustees og the Leland Standford Junior University Clinical- and industrial-scale intact-tissue sequencing

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0581600A (en) * 1991-04-18 1993-04-02 Fujitsu Ltd System monitoring processing system in hyperbolic navigation system
IL106610A0 (en) 1992-08-07 1993-12-08 Cytel Corp Hla binding peptides and their uses
ATE466869T1 (en) 1993-03-05 2010-05-15 Epimmune Inc METHOD FOR PRODUCING IMMUNOGENIC HLA-A2.1-BINDING PEPTIDES
US5856131A (en) * 1997-02-24 1999-01-05 Incyte Pharmaceuticals, Inc. Human selenoprotein
US7026447B2 (en) * 1997-10-09 2006-04-11 Human Genome Sciences, Inc. 53 human secreted proteins
JP2002507387A (en) 1997-12-24 2002-03-12 コリクサ コーポレイション Compounds for immunotherapy and diagnosis of breast cancer and methods for their use
WO1999037775A2 (en) * 1998-01-26 1999-07-29 Genquest, Inc. Compositions and methods for detecting and treating breast cancer
US6783961B1 (en) * 1999-02-26 2004-08-31 Genset S.A. Expressed sequence tags and encoded human proteins
CA2296792A1 (en) 1999-02-26 2000-08-26 Genset S.A. Expressed sequence tags and encoded human proteins
AU3395900A (en) 1999-03-12 2000-10-04 Human Genome Sciences, Inc. Human lung cancer associated gene sequences and polypeptides
US20020052308A1 (en) * 1999-03-12 2002-05-02 Rosen Craig A. Nucleic acids, proteins and antibodies
EP1248800A2 (en) 1999-11-30 2002-10-16 Corixa Corporation Compositions and methods for therapy and diagnosis of breast cancer
CA2413211A1 (en) * 2000-04-04 2001-10-11 University Of Rochester A gene differentially expressed in breast and bladder cancer and encoded polypeptides
AU2001255326B2 (en) * 2000-04-12 2005-12-15 University Of Rochester Targeted vaccine delivery systems
US20050196755A1 (en) 2000-11-17 2005-09-08 Maurice Zauderer In vitro methods of producing and identifying immunoglobulin molecules in eukaryotic cells
JP4368196B2 (en) 2000-11-17 2009-11-18 ユニバーシティー オブ ロチェスター In vitro methods for producing and identifying immunoglobulin molecules in eukaryotic cells
US7563882B2 (en) 2002-06-10 2009-07-21 University Of Rochester Polynucleotides encoding antibodies that bind to the C35 polypeptide
WO2005099361A2 (en) * 2003-07-10 2005-10-27 Vaccinex, Inc. MHC CLASS I - PEPTIDE-ANTIBODY CONJUGATES WITH MODIFIED β2-MICROGLOBULIN
EP1708751B1 (en) 2003-12-04 2011-09-28 Vaccinex, Inc. Methods of killing tumor cells by targeting internal antigens exposed on apoptotic tumor cells

Similar Documents

Publication Publication Date Title
AU2001253119A1 (en) A gene differentially expressed in breast and bladder cancer and encoded polypeptides
EP1531848A4 (en) Gene differentially expressed in breast and bladder cancer and encoded polypeptides
AU2003304203A1 (en) Differentially expressed genes involved in cancer, the polypeptides encoded thereby, and methods of using the same
AU2001253140A1 (en) Tumor markers in ovarian cancer
AU7721500A (en) Colon and colon cancer associated polynucleotides and polypeptides
AU2001278070A1 (en) Basal cell markers in breast cancer and uses thereof
EP1568773A2 (en) Sequence-determined DNA fragments and corresponding polypeptides encoded thereby
AU2225000A (en) Sequence-determined dna fragments and corresponding polypeptides encoded thereby
GB0002835D0 (en) Drug resistance in cancer
AU2001280608A1 (en) Human polynucleotides and polypeptides encoded thereby
AU2002362613A1 (en) Galectins-1-and-4 in tumor development
AU2002243314A1 (en) Immunogenic cancer peptides and uses thereof
AU4171001A (en) Membrane estrogen receptor-directed therapy in breast cancer
AU8026300A (en) Sodd gene expression in cancer
IL145775A0 (en) 13 transmembrane protein expressed in prostate cancer
IL145719A0 (en) Polypeptides encoded by nucleotide sequences expressed in breast tumor tissue and uses thereof
AU2002215111A1 (en) Ruthenium-aryl-compounds in cancer therapy
AU5416700A (en) Differentially expressed genes in prostate cancer
AU2001236782A1 (en) 34p3d7: a tissue specific protein highly expressed in prostate cancer
AU2001287004A1 (en) Xage-1, a gene expressed in multiple cancers, and uses thereof
AU2001238144A1 (en) 83p5g4: a tissue specific protein highly expressed in prostate cancer
AU2001268466A1 (en) 55p4h4: gene expressed in various cancers
GB2356437B (en) Improvements in swashplate design
AU2002364077A8 (en) Gene expression profiles in stomach cancer
AU1926699A (en) Cathepsin dc proteins, dna encoding the proteins, and their use in human cancer prognosis